Loncastuximab Tesirine and Acalabrutinib
IRB-300009213
Phase 1 small_molecule active
Quick answer
Loncastuximab Tesirine and Acalabrutinib for Chronic Lymphocytic Leukemia is a Phase 1 program (small_molecule) at ADC Therapeutics SA with 1 ClinicalTrials.gov record(s).
Program details
- Company
- ADC Therapeutics SA
- Indication
- Chronic Lymphocytic Leukemia
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active